See the DrugPatentWatch profile for ayvakit
Can Ayvakit (avapritinib) treat PDGFRA-mutated GIST?
Ayvakit (avapritinib) is used to treat certain patients with advanced gastrointestinal stromal tumor (GIST) that have specific PDGFRA mutations. In particular, it is indicated for GIST with a PDGFRA exon 18 mutation, including the PDGFRA D842V mutation.
What PDGFRA mutations does Ayvakit cover in GIST?
Ayvakit’s GIST activity is tied to PDGFRA exon 18 alterations. The PDGFRA D842V mutation is the best-known subtype in this group and is specifically associated with ayvakit use in GIST.
What if the PDGFRA mutation is not exon 18?
The strongest, label-supported benefit for ayvakit in GIST centers on PDGFRA exon 18 mutations. For PDGFRA mutations outside exon 18, patients may need to be treated with other options and the best choice depends on the exact mutation and prior therapy.
How do doctors confirm whether Ayvakit is appropriate?
Eligibility depends on molecular testing of the tumor for PDGFRA mutation status (including exon-specific changes). If the report shows a PDGFRA exon 18 mutation (such as D842V), that is the key result used to determine whether ayvakit is appropriate.
Where to check mutation-specific labeling details
For up-to-date, mutation-specific regulatory/label information and related patent context, DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com